WO2009072624A1 - ヘテロ環化合物による造血幹細胞の増幅方法 - Google Patents
ヘテロ環化合物による造血幹細胞の増幅方法 Download PDFInfo
- Publication number
- WO2009072624A1 WO2009072624A1 PCT/JP2008/072188 JP2008072188W WO2009072624A1 WO 2009072624 A1 WO2009072624 A1 WO 2009072624A1 JP 2008072188 W JP2008072188 W JP 2008072188W WO 2009072624 A1 WO2009072624 A1 WO 2009072624A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- positive cell
- hematopoietic stem
- stem cell
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/746,497 US20100310536A1 (en) | 2007-12-05 | 2008-12-05 | Method for expanding hematopoietic stem cells using heterocyclic compound |
JP2009544752A JP5573159B2 (ja) | 2007-12-05 | 2008-12-05 | ヘテロ環化合物による造血幹細胞の増幅方法 |
EP08858273A EP2228435A4 (en) | 2007-12-05 | 2008-12-05 | METHOD FOR AMPLIFYING HEMATOPOIETIC STRAIN CELL USING HETEROCYCLIC COMPOUND |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007315165 | 2007-12-05 | ||
JP2007-315165 | 2007-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009072624A1 true WO2009072624A1 (ja) | 2009-06-11 |
Family
ID=40717802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/072188 WO2009072624A1 (ja) | 2007-12-05 | 2008-12-05 | ヘテロ環化合物による造血幹細胞の増幅方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20100310536A1 (ja) |
EP (1) | EP2228435A4 (ja) |
JP (1) | JP5573159B2 (ja) |
WO (1) | WO2009072624A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010140685A1 (ja) * | 2009-06-04 | 2010-12-09 | 日産化学工業株式会社 | ヘテロ環化合物及び造血幹細胞の増幅剤 |
JPWO2009072626A1 (ja) * | 2007-12-05 | 2011-04-28 | 日産化学工業株式会社 | ヘテロ環化合物による造血幹細胞の増幅方法 |
JPWO2009072625A1 (ja) * | 2007-12-05 | 2011-04-28 | 日産化学工業株式会社 | ヘテロ環化合物による造血幹細胞の増幅方法 |
WO2012074068A1 (ja) * | 2010-12-01 | 2012-06-07 | 日産化学工業株式会社 | ピラゾール化合物による造血幹細胞の製造方法 |
WO2013051625A1 (ja) | 2011-10-03 | 2013-04-11 | 日産化学工業株式会社 | 多能性幹細胞からの巨核球及び/又は血小板の製造方法 |
JP5511039B1 (ja) * | 2013-05-22 | 2014-06-04 | 国立大学法人九州大学 | Nk細胞の調製方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11697799B2 (en) | 2019-04-15 | 2023-07-11 | Ossium Health, Inc. | System and method for extraction and cryopreservation of bone marrow |
WO2022020210A1 (en) | 2020-07-18 | 2022-01-27 | Ossium Health, Inc. | Permeation of whole vertebral bodies with a cryoprotectant using vacuum assisted diffusion |
AU2021360590A1 (en) | 2020-10-14 | 2023-06-15 | Ossium Health, Inc. | Systems and methods for extraction and cryopreservation of bone marrow |
EP4262831A1 (en) | 2020-12-18 | 2023-10-25 | Ossium Health, Inc. | Methods of cell therapies |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002502617A (ja) | 1998-02-17 | 2002-01-29 | ガミダ セル リミテッド | 幹細胞および前駆細胞の増殖と分化を制御する方法 |
JP2006506452A (ja) * | 2002-10-09 | 2006-02-23 | 日産化学工業株式会社 | ピラゾロン化合物及びトロンボポエチンレセプター活性化剤 |
JP2006061106A (ja) | 2004-08-27 | 2006-03-09 | Hiroo Iwata | 造血幹細胞の製造方法 |
WO2006062247A1 (ja) * | 2004-12-08 | 2006-06-15 | Nissan Chemical Industries, Ltd. | 置換複素環化合物及びトロンボポエチンレセプター活性化剤 |
WO2006062240A1 (en) * | 2004-12-08 | 2006-06-15 | Nissan Chemical Industries, Ltd. | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators |
WO2006062249A1 (ja) * | 2004-12-08 | 2006-06-15 | Nissan Chemical Industries, Ltd. | 置換ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
WO2006064957A1 (ja) | 2004-12-14 | 2006-06-22 | Nissan Chemical Industries, Ltd. | アミド化合物及びトロンボポエチンレセプター活性化剤 |
JP2006527187A (ja) * | 2003-06-06 | 2006-11-30 | 日産化学工業株式会社 | ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
WO2007052808A1 (ja) * | 2005-11-07 | 2007-05-10 | Nissan Chemical Industries, Ltd. | ヒドラジド化合物及びトロンボポエチンレセプター活性化剤 |
WO2007142308A1 (ja) * | 2006-06-07 | 2007-12-13 | Nissan Chemical Industries, Ltd. | 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030044978A1 (en) * | 1998-02-05 | 2003-03-06 | Novartis Corporation | Expanded and genetically modified populations of human hematopoietic stem cells |
CA2318819A1 (en) * | 1998-02-05 | 1999-08-12 | Novartis Ag | Expanded and genetically modified populations of human hematopoietic stem cells |
JPWO2003014336A1 (ja) * | 2001-08-07 | 2004-11-25 | 麒麟麦酒株式会社 | 造血幹細胞の製造法 |
EP2228434A4 (en) * | 2007-12-05 | 2013-01-23 | Nissan Chemical Ind Ltd | Amplification method for hematopoietic stem cells with heterocyclic compound |
EP2233561A4 (en) * | 2007-12-05 | 2013-01-16 | Nissan Chemical Ind Ltd | METHOD FOR AMPLIFYING HEMATOPOIETIC STRAIN CELL USING HETEROCYCLIC COMPOUND |
-
2008
- 2008-12-05 JP JP2009544752A patent/JP5573159B2/ja not_active Expired - Fee Related
- 2008-12-05 EP EP08858273A patent/EP2228435A4/en not_active Withdrawn
- 2008-12-05 US US12/746,497 patent/US20100310536A1/en not_active Abandoned
- 2008-12-05 WO PCT/JP2008/072188 patent/WO2009072624A1/ja active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002502617A (ja) | 1998-02-17 | 2002-01-29 | ガミダ セル リミテッド | 幹細胞および前駆細胞の増殖と分化を制御する方法 |
JP2006506452A (ja) * | 2002-10-09 | 2006-02-23 | 日産化学工業株式会社 | ピラゾロン化合物及びトロンボポエチンレセプター活性化剤 |
JP2006527187A (ja) * | 2003-06-06 | 2006-11-30 | 日産化学工業株式会社 | ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
JP2006061106A (ja) | 2004-08-27 | 2006-03-09 | Hiroo Iwata | 造血幹細胞の製造方法 |
WO2006062247A1 (ja) * | 2004-12-08 | 2006-06-15 | Nissan Chemical Industries, Ltd. | 置換複素環化合物及びトロンボポエチンレセプター活性化剤 |
WO2006062240A1 (en) * | 2004-12-08 | 2006-06-15 | Nissan Chemical Industries, Ltd. | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators |
WO2006062249A1 (ja) * | 2004-12-08 | 2006-06-15 | Nissan Chemical Industries, Ltd. | 置換ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
WO2006064957A1 (ja) | 2004-12-14 | 2006-06-22 | Nissan Chemical Industries, Ltd. | アミド化合物及びトロンボポエチンレセプター活性化剤 |
WO2007052808A1 (ja) * | 2005-11-07 | 2007-05-10 | Nissan Chemical Industries, Ltd. | ヒドラジド化合物及びトロンボポエチンレセプター活性化剤 |
WO2007142308A1 (ja) * | 2006-06-07 | 2007-12-13 | Nissan Chemical Industries, Ltd. | 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤 |
Non-Patent Citations (23)
Title |
---|
ASTORI G, BONE MARROW TRANSPLANT, vol. 35, 2005, pages 1101 |
CASSEL, A. ET AL., EXP. HEMATOL., vol. 21, 1993, pages 585 - 91 |
CHUTE, JP ET AL., PROC NATL ACAD SCI USA., vol. 103, 2006, pages 11707 - 12 |
CWIRLA, S.E. ET AL.: "Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine", SCIENCE, vol. 276, no. 5319, 1997, pages 1696 - 1699, XP008136351 * |
EMA, H. ET AL., BLOOD, vol. 75, 1990, pages 1941 - 6 |
ISHIZAWA, L. ET AL., J HEMATOTHER., vol. 2, 1993, pages 333 - 8 |
KAUSHANSKY, K ET AL., ANN NY ACAD SCI., vol. 1044, 2005, pages 139 - 141 |
KOLLER MR, BONE MARROW TRANSPLANT, vol. 21, 1998, pages 653 |
KOLLER, MR, BLOOD, vol. 82, 1993, pages 378 |
KURTZBERT, J. ET AL., NEW ENG. J. MED., vol. 335, 1996, pages 157 - 66 |
LAM AC ET AL., TRANSFUSION, vol. 41, no. 12, December 2001 (2001-12-01), pages 1567 - 76 |
LEUNG, AY ET AL., EXP HEMATOL., vol. 33, 2005, pages 422 - 7 |
LIU, J. ET AL.: "Ex vivo expansion of enriched CD34+ cells from neonatal blood in the presence of thrombopoietin, a comparison with cord blood and bone marrow", BONE MARROW TRANSPLANT., vol. 24, no. 3, 1999, pages 247 - 252, XP008136342 * |
LU, L. ET AL., EXP. HEMATOL., vol. 11, 1983, pages 721 - 9 |
MILHEM, M ET AL., BLOOD., vol. 103, 2004, pages 4102 - 10 |
NAKAMURA, T. ET AL.: "A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis", BLOOD, vol. 107, no. 11, 2006, pages 4300 - 4307, XP008136356 * |
ORLIC, D ET AL., NATURE, vol. 410, 2001, pages 701 - 5 |
ROSLER, E ET AL., EXP HEMATOL., vol. 28, 2000, pages 841 - 52 |
SCHWARTZ RM, PROC. NATL. ACAD. SCI. U.S.A., vol. 88, 1991, pages 6760 |
See also references of EP2228435A4 * |
SHIMAKURA, Y ET AL., STEM CELLS, vol. 18, 2000, pages 183 - 9 |
TAGUCHI, A ET AL., J CLIN INVEST., vol. 114, 2004, pages 330 - 8 |
TATEISHI-YUYAMA, E ET AL., LANCET, vol. 360, 2002, pages 427 - 35 |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5573160B2 (ja) * | 2007-12-05 | 2014-08-20 | 日産化学工業株式会社 | ヘテロ環化合物による造血幹細胞の増幅方法 |
JPWO2009072626A1 (ja) * | 2007-12-05 | 2011-04-28 | 日産化学工業株式会社 | ヘテロ環化合物による造血幹細胞の増幅方法 |
JPWO2009072625A1 (ja) * | 2007-12-05 | 2011-04-28 | 日産化学工業株式会社 | ヘテロ環化合物による造血幹細胞の増幅方法 |
US9115341B2 (en) | 2007-12-05 | 2015-08-25 | Nissan Chemical Industries, Ltd. | Method for expanding hematopoietic stem cells using heterocyclic compound |
JP5573161B2 (ja) * | 2007-12-05 | 2014-08-20 | 日産化学工業株式会社 | ヘテロ環化合物による造血幹細胞の増幅方法 |
EP2439204A1 (en) * | 2009-06-04 | 2012-04-11 | Nissan Chemical Industries, Ltd. | Heterocyclic compound and hematopoietic stem cell amplifier |
WO2010140685A1 (ja) * | 2009-06-04 | 2010-12-09 | 日産化学工業株式会社 | ヘテロ環化合物及び造血幹細胞の増幅剤 |
EP2439204A4 (en) * | 2009-06-04 | 2012-06-20 | Nissan Chemical Ind Ltd | HETEROCYCLIC CONNECTION AND HEMATOPOIETIC STEM CELL AMPLIFIER |
US9328085B2 (en) | 2009-06-04 | 2016-05-03 | Nissan Chemical Industries, Ltd. | Heterocyclic compounds and expansion agents for hematopoietic stem cells |
WO2012074068A1 (ja) * | 2010-12-01 | 2012-06-07 | 日産化学工業株式会社 | ピラゾール化合物による造血幹細胞の製造方法 |
US9212348B2 (en) | 2010-12-01 | 2015-12-15 | Nissan Chemical Industries, Ltd. | Method for producing hematopoietic stem cells using pyrazole compounds |
JP5946775B2 (ja) * | 2010-12-01 | 2016-07-06 | 日産化学工業株式会社 | ピラゾール化合物による造血幹細胞の製造方法 |
KR20140082673A (ko) | 2011-10-03 | 2014-07-02 | 닛산 가가쿠 고교 가부시키 가이샤 | 다능성 간세포로부터의 거핵구 및/또는 혈소판의 제조 방법 |
WO2013051625A1 (ja) | 2011-10-03 | 2013-04-11 | 日産化学工業株式会社 | 多能性幹細胞からの巨核球及び/又は血小板の製造方法 |
JP2014226079A (ja) * | 2013-05-22 | 2014-12-08 | 国立大学法人九州大学 | Nk細胞の調製方法 |
JP5511039B1 (ja) * | 2013-05-22 | 2014-06-04 | 国立大学法人九州大学 | Nk細胞の調製方法 |
Also Published As
Publication number | Publication date |
---|---|
JP5573159B2 (ja) | 2014-08-20 |
US20100310536A1 (en) | 2010-12-09 |
JPWO2009072624A1 (ja) | 2011-04-28 |
EP2228435A4 (en) | 2013-01-23 |
EP2228435A1 (en) | 2010-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009072624A1 (ja) | ヘテロ環化合物による造血幹細胞の増幅方法 | |
WO2009072626A1 (ja) | ヘテロ環化合物による造血幹細胞の増幅方法 | |
WO2009072625A1 (ja) | ヘテロ環化合物による造血幹細胞の増幅方法 | |
WO2009072635A1 (ja) | ヘテロ環化合物による造血幹細胞の増幅方法 | |
SG179207A1 (en) | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | |
MX356756B (es) | Células madre pluripotentes en microportadores. | |
WO2007103550A3 (en) | Substituted aminothiazole derivatives with anti-hcv activity | |
TW200732306A (en) | Pyrimidine derivatives | |
TW200716648A (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | |
MX358682B (es) | Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4). | |
EA200800726A1 (ru) | Введение ингибиторов дипептидилпептидазы | |
MX2008013582A (es) | Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa. | |
IN2012DN00755A (ja) | ||
WO2008079787A3 (en) | Glucokinase activators | |
TW200740815A (en) | P38 MAP kinase inhibitors and methods for using the same | |
NZ579928A (en) | Fluorinated derivatives of deferiprone | |
WO2008116107A3 (en) | Piperazine derivatives as glucokinase activators | |
TW200616976A (en) | Pyrimidine derivatives | |
NZ599138A (en) | Purine derivatives useful as hsp90 inhibitors | |
TW200745137A (en) | Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | |
HK1125291A1 (en) | Method of using guava extract and composition including guava extract | |
WO2008114812A1 (ja) | Jak阻害剤 | |
WO2007143117A3 (en) | Differentiation of primate pluripotent cells to hepatocyte-lineage cells | |
EP2581442A4 (en) | PROCESS FOR PRODUCING HEMATOPOIETIC STEM CELLS | |
EP1679964A4 (en) | COMPOSITIONS AND METHODS USING ARNS, AMPHIPATHIC COMPOUNDS AND POLYCATIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08858273 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009544752 Country of ref document: JP |
|
REEP | Request for entry into the european phase |
Ref document number: 2008858273 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008858273 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12746497 Country of ref document: US |